# This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye

> **NCT07490535** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Pittsburgh Research Institute** · enrollment: 36 (estimated)

## Conditions studied

- Ocular Surface Disease
- Dry Eye Syndrome (DES)

## Interventions

- **DRUG:** (Xiidra®) Lifitegrast Ophthalmic Solution 5.0%

## Key facts

- **NCT ID:** NCT07490535
- **Lead sponsor:** Pittsburgh Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2026-09
- **Final completion:** 2026-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490535, "This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07490535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*